



NEW THERAPEUTICS FOR AGING DISEASES

[Press Release](#)

BIOPHYTIS Invited to Attend the Jefferies 2015 Global Healthcare Conference

Romainville (France), November 10, 2015 – BIOPHYTIS (Alternext Paris: ALBPS), a geriatric medicine company advancing clinical stage drug-candidates to treat sarcopenic obesity and age related macular degeneration (AMD), today announced that it will meet leading institutional investors at the Jefferies 2015 Global Healthcare Conference on November 18-19, 2015, at The May Fair Hotel in London.

During this international event, Stanislas Veillet, CEO of BIOPHYTIS, will present the Company and review its clinical stage programs, SARCOB (BIO101, BO103) to treat sarcopenic obesity and, MACULIA (BIO201, BIO203) to treat dry AMD.

SARCOB drug candidates are orally available selective MAS receptor agonists, which have demonstrated preclinical proof of concept for sarcopenic obesity and satisfactory safety and tolerability in clinical Phase I testing. Preparations for Phase IIb clinical trial are ongoing. To learn more, please visit: <http://www.biophytis.com/en/pipeline/plateforme-sarcob/>

MACULIA drug candidates are orally available subtype selective PPAR alpha agonists, which have demonstrated preclinical proof of concept for age related macular degeneration and satisfactory safety and tolerability in Phase I testing. Preparations for Phase IIb clinical trial are ongoing. To learn more, please visit: <http://www.biophytis.com/en/pipeline/plateforme-maculia/>

About BIOPHYTIS:

BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need.

The company was founded by researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at ICAN (Institute of Cardiometabolism and Nutrition), and the Institute of Myology, and the Vision Institute.

BIOPHYTIS is eligible for the French PEA-PME regime

ALBPS
LISTED
ALTERNEXT



Contacts :

BIOPHYTIS

Stanislas VEILLET

CEO

contact@biophytis.com

Tel : +33 (0) 1 41 83 66 00

Milestones – Press & Investors relations

Bruno ARABIAN

barabian@milestones.fr

Tel : +33 (0) 1 83 62 34 84 / +33 (0) 6 87 88 47 26